Gilead CEO in the congressional hot seat

Gilead CEO Daniel O’Day will be in the hot seat this morning as the House Committee on Oversight and Reform holds a hearing on how the company priced its $20,000-a-year HIV drug Truvada. A new lawsuitalleges Gilead struck anti-competitive deals with other companies to maintain its monopoly over the drug. The company is also fighting critics who say that since taxpayer money partly funded the initial development of Truvada, the company should broaden access to the medication.

There’s also a full House vote planned for today, where members will vote on a combined package of health care bills: legislation to lower prescription drug costs and more contentious Obamacare bills. The bundling, lawmakers said, has lost Republican support and turned an orderly process into what one lawmaker termed a "food fight."